AMD forgot to launch HYPR-RX
The company has not delivered on its promise to introduce HYPR-RX performance mode in the first half of 2023.
The HYPR-RX was meant to be a simple solution that combines three technologies focusing on performance and responsiveness. AMD did not launch HYPR-RX in the first half of 2023 as promised, even though it appeared to be an easy feature to implement.
AMD HYPR-RX was meant to give an easy one-click performance mode based on three AMD technologies: Radeon Super Resolution, Radeon Boost and Radeon Anti-Lag. The first one works like FidelityFX Super Resolution 1.0, in fact, it is based on the same algorithm. However, instead of relying on game developers to implement AMD upscaling tech, the company figured a way to upscale the whole frame across all games on a driver level. This feature is now commonly used on low-power gaming consoles like Steam Deck.
AMD Radeon Boost can dynamically lower the resolution when motion is detected in a frame. For dynamic and fast-paced content, this could improve responsiveness and performance. For newer games, Radeon Boost uses a DirectX12 feature called Variable Rate Shading.
The third pillar of HYPR-RX is Anti-Lag, which is more or less AMD implementation of NVIDIA Reflex, both technologies are designed to cut input lag to minimum and efficiently control CPU work. In the end, gamers get higher responsiveness which is proven useful in dynamic scenes.
Given what AMD has already shown, the HYPR-RX would act as a built-in profile into AMD Software. Gamers would have an option to enable or disable individual features or go an easy way to globally enforce optimized settings through HYPR-RX.
However, it is currently not possible to enable all features at once. The Radeon Super Resolution, as an example, does not work with Radeon Boost. Both features are mutually exclusive, shows a message in Radeon software. The same applies to Radeon Boost and Anti-Lag, these do not work together either.
AMD HYPR-RX was announced in November last year alongside FSR 3.0. The company has been tight-lipped on FSR3 and HYPR-RX for almost 8 months and neither technology has a release date.